ABSTRACT
INTRODUCTION
Hotspot mutations in BRAF and NRAS are well-established driver mutations in the MAPK pathway (RAF-MEK-ERK signal transduction cascade), which occurs in over 50% and 20% of melanomas, respectively (1) . The identification of oncogenic mutations in BRAF, predominantly at codon 600 (2) , was the main driving force in the development of small molecule inhibitors targeting MAPK kinase kinases (MEK) and BRAF in melanoma, which includes vemurafenib and dabrafenib. Patients with BRAF mutant melanomas treated with RAF and MEK inhibitors have significant improvement in progression-free and overall survival as single agents (3) (4) (5) (6) . Patient survival is further improved with the use of combination treatment of RAF and MEK inhibitors (7) .
However, most patients treated with vemurafenib and dabrafenib develop disease progression within 6-8 months (reviewed in (8, 9) ). In addition, some patients present with intrinsic resistance (often termed de novo) that do not respond at all or have shortlived responses to RAF inhibitors progressing on drug treatment in less than 12 weeks.
Recently, two large-scale whole exome sequencing (WES) studies have revealed that in addition to recurrent mutations in BRAF and NRAS, the next most frequently observed somatic hotspot mutation in melanoma of cutaneous origin is the RAC1 c.85C>T single nucleotide variant (SNV) encoding the P29S amino acid change found in approximately 4-9% of melanomas (10, 11) . RAC1 is a member of the Rho family of small GTP-binding proteins whose activity has been implicated in tumorigenesis and metastasis (12) . RAC1 transduces extracellular signals from growth factor, integrin, and G-protein-coupled receptors, and its best-characterized function is in the regulation of cytoskeleton rearrangement (13) . Although the RAC1 P29S mutation has been shown to be oncogenic and biochemically active (10, 11, 14) , the biological role and clinical relevance of the RAC1 hotspot mutation in melanoma remains unclear. Recent publications on genomic characterization of matched pre-and post-treated melanoma Author Manuscript Published OnlineFirst on July 23, 2014; DOI: 10.1158/0008-5472.CAN-14-1232-T samples from patients who received RAF and MEK inhibitors (15) (16) (17) (18) (19) have confirmed many of the acquired resistance mechanisms identified in preclinical in vitro studies (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . In one such study, the authors observed a significant correlation of the RAC1 P29S hotspot mutation and early resistance in patients who received vemurafenib or dabrafenib monotherapy (17) . Here, we present functional data supporting a role for the RAC1 P29S mutation in resistance to RAF inhibitors by maintaining activation of the MAPK signaling pathway. Our results suggest that RAC1 P29S status in melanoma may be an important predictor for vemurafenib and dabrafenib resistance in patients, and consequently should be evaluated as a predictive biomarker to such therapies in the clinic.
MATERIALS AND METHODS

Sequenom and Sanger sequencing
gDNA was isolated using DNeasy Blood & Tissue Kit (Qiagen). Mass spectrometric genotyping (Sequenom) was performed as previously described (10, 30) . Sequenom was employed to test all cell lines used in this study for RAC1, BRAF, and RAS family member hostpot mutations. Confirmation of the RAC1 c.85C>T SNV encoding for amino acid change P29S was validated by amplifying exon 2 with forward (TGCTAACACCGGGTACCTAAAC) and reverse (TCATCCAGTCTCTGTACCTCAC) primers. PCR products were purified by QIAquick Gel Extraction Kit (Qiagen) followed by bidirectional sequencing with forward (TTTTAACTTAATAGTGAAAGCTA) and reverse (TGGTCAAAGAAATGTGAAAC) primers on ABI 3730 DNA sequencers using Big Dye terminator cycle sequencing chemistry. RAC1 activation assays were performed as previously described according to the manufacturer's protocol (Cell Biolabs) (10). 
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RESULTS
RAC1 P29S Mutant Melanoma Cell Lines Have Higher Levels of Activated RAC1 and Display Differential Sensitivity to RAF and MEK Inhibitors
To determine the biological role of the RAC1 c.85C>T SNV encoding for the P29S amino acid change, we probed the RAC1 P29S variant status in a panel of melanoma cell lines by mass spectrometry genotyping (sequenom) (10) . We identified two melanoma cell lines with SNV encoding for S29 (IGR1 and WM3060), which were confirmed by PCR and Sanger re-sequencing (Supplementary Figure 1) . We documented by sequenom genotyping and Sanger re-sequencing that IGR1 cells harbor a co-occurring BRAF c.1798_1799GT>AA dinucleotide variant (DNV) encoding the V600K amino acid change, whereas the WM3060 melanoma possesses a NRAS Q61K mutation (data not shown). It has been shown that RAC1 P29S is found in a higher active GTP-loaded fraction compared to the wild-type protein (10, 11, 33) as measured by RAC1 interaction with the p21-binding domain (PBD) of p21-activated protein kinase (PAK) (34) . We demonstrate that endogenous RAC1 is found in a higher active fraction in PBD-binding assays in cell lines with P29S compared with ones with wild-type ( Figure 1A , compare lanes 7, 10, 13, and 16; and Supplementary Figure 2A) , confirming that melanoma cell lines with P29S possess higher levels of activated RAC1.
To investigate the functional role of RAC1 P29S variant in melanoma, we treated Table 2 ). These results suggested that RAC1 P29S modulates sensitivity to inhibitors of the MAPK pathway in melanoma.
RAC1 P29S Mediates Resistance to RAF and MEK Inhibition
To assess whether RAC1 P29S promotes resistance to RAF and MEK inhibition, we stably infected 451Lu cells with GFP, RAC1 wild-type (WT), and P29S expressing We next examined the apoptotic response to RAF inhibition in our isogenic cell lines by immunoblotting for cleaved-PARP in lysates from GFP and RAC1 P29S overexpressing A375 and 451Lu cells treated with dabrafenib. Consistent with our viability assays, we observed reduced apoptosis in response to RAF inhibition in cell lines overexpressing P29S ( Figure 3A and B) . Similar results were observed in MALME-3M cell lines overexpressing P29S (Supplementary Figure 5D) . In addition, P29S expressing cells maintained elevated MAPK signaling activity as measured by phospho-MAP2K1/MAP2K2 (MEK1/2) S217/S221 levels in response to RAF inhibitor treatment compared to GFP controls ( Figure 3C ).
Complementing the gain-of-function studies above, we generated IGR1 cells stably expressing doxycycline (DOX)-inducible RAC1 shRNAs. Upon administration of DOX for 72h we observed a decrease in RAC1 protein levels with multiple independent shRNAs compared to two controls (shGFP and shLuciferase) ( Figure 3D 
RAC1 P29S Decreases Effect of RAF Inhibitor on Tumor Growth in vivo
To evaluate how the RAC1 P29S mutant modulates the response to RAF inhibitors in vivo, we implanted the A375 isogenic cells described above in NCR-nude mice. When an approximate 100-250 mm 3 tumor volume was observed, mice were switched to chow admixed with PLX4720, a preclinical RAF inhibitor (35) . This formulation has previously been shown to deliver high and stable serum concentration through course of treatment in mice (36) . As shown in Figure 4A , wild-type and GFP controls showed initial regression followed by stable disease over a 19 day course of PLX4720 treatment (tumor growth inhibition (TGI) of GFP group=55%; WT group=64%; p=not significant). In contrast, RAC1 P29S mutant expressing tumors continued to grow with accelerated rate on treatment (TGI=280%), achieving significantly higher tumor days, p<0.001) ( Figure 4D ).
DISCUSSION
In this study, we identified melanoma cell lines possessing the RAC1 P29S variant and demonstrated that RAC1 is present in a higher GTP-active fraction compared to cell lines of similar genotype/origin. We should note, although some melanoma oncogenes and tumor suppressors are known to be involved in familial melanoma, the RAC1 P29S somatic mutation is caused by presumptive UVB-induced DNA damage and misrepair (C>T transition) (10, 11) , and has not been detected as a germline mutation in the 1000 Genomes databases or among over 2,500 germline P29S as a RAF inhibitor resistance mutation in melanoma.
Our conclusion is supported by clinical data from a recent study of 45 patients that received vemurafenib and dabrafenib monotherapy where pre-and post-treatment BRAF V600-mutant metastatic samples underwent WES analysis (17) . Of the 45 patient data examined, 14 acquired resistance early in the course of treatment. Interestingly, the three patients in this cohort of 45 with RAC1 P29S mutation were all found to belong to this early resistance subgroup. The P29S mutation was not found in any melanoma sample from patients that had a sustained response to therapy in this study (the enrichment in the early resistant group was found to be statistically significant).
Together, this clinical correlation in context of our functional results would suggest that RAC1 P29S status in melanoma may not only confer vemurafenib and dabrafenib resistance, but may predict those patients with intrinsic resistance to this class of targeted therapy. However, we acknowledge that an adequately powered study in the clinic will be necessary to definitively demonstrate the utility of RAC1 hotspot mutation in predicting intrinsic resistance to RAF inhibitors.
Mechanistically, our studies suggest that RAC1 P29S may sustain MAPK signaling in the presence of RAF inhibitors. Phospho-MEK1/2 levels were elevated in A375 isogenic cell lines overexpressing RAC1 P29S in response to dabrafenib, and we observed levels of phospho-MEK1/2 S217/S221 and phospho-ERK1/2 T202/Y204 decreased following RAC1 knockdown of endogenous RAC1 P29S in IGR1 cells. This is consistent with previous studies implicating RAC1 in the regulation of MAPK signaling (reviewed in (12)), and a recent study demonstrating RAC1 P29S can induce ERK phosphorylation in melanocytes (11) . A number of studies have identified RAF inhibitor resistance mechanisms, which can be broadly characterized into groups that include reactivation of the MAPK pathway, upregulation of the PI3K-PTEN-AKT pathway, and 
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dysregulation of melanocytic signaling (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . We cannot exclude the possibility that there may be alternative mechanisms that RAC1 P29S can drive RAF inhibitor resistance, including upstream or parallel to the MAPK pathway. Investigation of the aberrant oncogenic signaling caused by the RAC1 hotspot mutation in melanoma, and potential combination therapies to target this mutation, remains an important area of investigation for future study. 
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